![]() ![]() Ocriplasmin treatment was offered to patients of the second group at the discretion of the treating physician, if he assumed that release of the VMT would improve the clinical course of the underlying macular disease, and patients were reluctant to undergo a vitrectomy. The second group (15 eyes) had VMT with or without a FTMH, but this was part of the macular pathology. The first group (20 eyes) included patients having VMT with or without FTMH on spectral domain optical coherence tomography (SDOCT) but without any other macular pathology. A total of 35 patients (35 eyes) were identified. The records of all patients undergoing intravitreal ocriplasmin injection for VMT in the Ophthalmology Department, Academic Teaching Hospital Feldkirch, Austria, from October 2013 to December 2015 were retrospectively reviewed. ![]() Purpose of this study was to evaluate the effect of vitreolysis with ocriplasmin as an alternative, less invasive procedure compared to vitrectomy for the treatment of VMT in cases of concomitant macular pathology. Moreover, abnormalities of the vitreomacular interface in terms of VMT are possible risk factors for development of postoperative macular oedema after cataract surgery. In the case of DME elimination of any concomitant VMT and posterior vitreous detachment with vitrectomy has been shown to result in reduction of retinal thickening and improvement of visual acuity (VA) (Haller et al. In neovascular AMD, VMT has been considered to have some deleterious interaction with the underlying disease and a negative impact upon treatment outcomes with antivascular endothelial growth factor injections (anti-VEGF) (Krishnan et al. Vitreomacular traction can, however, occur alongside of another primary disease like AMD, DME or retinal vein occlusion. Since in the MIVI-TRUST trials age-related macular degeneration (AMD), diabetic macular oedema (DME), retinal vascular occlusion and previous intravitreal injection were exclusion criteria, present treatment guidelines restrict the use of ocriplasmin for the treatment of idiopathic (isolated) VMT. Pharmacologic vitreolysis with the use of ocriplasmin has emerged as a new option for the treatment of VMT with or without full thickness macular hole (FTMH) based on the results of the MIVI-TRUST trials (Stalmans et al. Until recently vitrectomy was the only treatment for vitreomacular traction syndrome (VMT).
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |